{
  "chapter_title": "Financials",
  "section_title": "Financial Statements / Metrics",
  "description": "Income statements, balance sheets, key performance metrics.",
  "questions": [
    {
      "question": "What are the key financial metrics presented in Ion Beam Applications SA's income statements and balance sheets that indicate its revenue growth, profitability, and liquidity?",
      "queries": [
        {
          "query": "Ion Beam Applications SA income statement key performance indicators",
          "results": [
            {
              "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "balance sheet metrics for Ion Beam Applications SA",
          "results": [
            {
              "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "financial ratios for Ion Beam Applications SA",
          "results": [
            {
              "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "How does Ion Beam Applications SA's financial situation compare to its industry peers in terms of debt-to-equity ratio, return on equity, and asset turnover?",
      "queries": [
        {
          "query": "Ion Beam Applications SA financial performance compared to industry peers",
          "results": [
            {
              "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "debt-to-equity ratio analysis for Ion Beam Applications SA",
          "results": [
            {
              "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "return on equity calculation for Ion Beam Applications SA",
          "results": [
            {
              "text": "STATUTORY AUDITOR'S REPORT TO THE GENERAL SHAREHOLDERS MEETING OF ION \nBEAM APPLICATION SA ON THE CONSOLIDATED ACCOUNTS FOR THE YEAR ENDED \n31 DECEMBER 2023",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "What are the trends in Ion Beam Applications SA's key performance metrics, such as operating margin, net income margin, and cash flow margin, over a specified period?",
      "queries": [
        {
          "query": "operating margin trend analysis for Ion Beam Applications SA",
          "results": [
            {
              "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "cash flow margin calculation for Ion Beam Applications SA",
          "results": [
            {
              "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "net income margin analysis for Ion Beam Applications SA",
          "results": [
            {
              "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "How does Ion Beam Applications SA's financial health and stability impact its creditworthiness, considering factors such as leverage, interest coverage, and cash flow generation?",
      "queries": [
        {
          "query": "credit risk assessment for Ion Beam Applications SA",
          "results": [
            {
              "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "leverage ratio analysis for Ion Beam Applications SA",
          "results": [
            {
              "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "interest coverage calculation for Ion Beam Applications SA",
          "results": [
            {
              "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    }
  ]
}